Clinical Trial Update: Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial investigating fourth-ventricular administration of nivolumab with methotrexate or 5-azacytidine for recurrent medulloblastoma, ependymoma, and o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasms
• Ependymoma
• Medulloblastoma

Drugs mentioned

• 5-Azacytidine (5-azacytidine)
• METHOTREXATE (METHOTREXATE)
• nivolumab (nivolumab)

Snippet

Sponsor: Jeffrey Treiber | Conditions: Recurrent Ependymoma, Recurrent Medulloblastoma | Phase 1 | Status: WITHDRAWN